TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

Clinical trial NCT05980598 · TERMINATED

Trial details

NCT number: NCT05980598
Sponsor: Ascendis Pharma A/S
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Neoplasms

Start date: 2023-09-29
Primary completion: 2025-03-28
Enrollment: 27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.